PEG Ratio

The PEG ratio, which measures stock price relative to earnings growth, stands at 0.56x for Biogen, meaning the current price is low compared to its expected profit growth.

Biogen’s PEG ratio is below the healthcare sector median of 0.77x, placing it in the 36th percentile among peers — indicating it is cheaper than most companies in its industry. The metric’s year-over-year change and quarter-over-quarter change are both listed as N/A, and no trend information is available for the last eight quarters. Because the value is low relative to peers but lacks any observable movement, the current level suggests the stock may be undervalued, but the absence of trend data prevents assessing whether this discount is widening or narrowing. This metric supports the overall NEUTRAL verdict, as the low PEG ratio points to a potential opportunity, while the lack of trend data and the stock’s average ranking among peers introduce caution.

Frequently Asked Questions

Closest Sector Peers